Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Vitor Abreu de Goes
Observed names:
V A De Goes,
V. Abreu de Goes,
Vitor Abreu De Goes,
Vitor Abreu Goes,
Vitor Abreu de Góes,
Vitor Goes,
Vitor Góes
show all 7
Institutions:
City Of Hope National Medical Center,
Hospital Israelita Albert Einstein,
City of Hope,
Beckman Research Institute
Observed institutions:
City Of Hope National Medical Center,
Hospital Israelita Albert Einstein,
City of Hope,
Beckman Research Institute
ORCID:
0000-0003-3521-6496
Observed ORCID:
0000-0003-3521-6496
OpenAlex ID:
A5104988700
Complement System in Brain Architecture and Neurodevelopmental Disorders
2020
·
Juliana Magdalon
, Fernanda Mansur
, et al.
·
Frontiers in Neuroscience
·
110
PDF
Microbiome Signatures in Advanced Gastric Cancer: Emerging Biomarkers for Risk Stratification, Therapy Guidance, and Prognostic Insight
2026
·
Kyung-il John Kim
, Hannah Zhong
, et al.
·
International Journal of Molecular Sciences
·
4
PDF
Assessing Geographic Disparities in the Availability of Renal Cell Carcinoma Clinical Trials in the United States
2026
·
George Zhang
, Jadon Fann
, et al.
·
JCO Oncology Practice
·
3
Clinical Predictors and Prognostic Significance of Pathologic Disease Upstaging at Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer
2025
·
Salvador Jaime-Casas
, Wesley Yip
, et al.
·
Cancers
·
3
PDF
Regional Variation in Bladder Cancer Clinical Trial Availability in the US
2026
·
Koral U. Shah
, Salvador Jaime-Casas
, et al.
·
JAMA Network Open
·
2
Evaluating Worldwide Disparities in Bladder Cancer Clinical Trial Availability
2025
·
Koral U. Shah
, Daniela V. Castro
, et al.
·
Cancers
·
2
The role of autologous bone marrow transplantation in primary effusion lymphoma: a case report and literature review
2024
·
Vitor Abreu de Goes
, Anita Cassoli Cortez
, et al.
·
Hematology Transfusion and Cell Therapy
·
2
Evaluating Global Disparities in the Availability of Prostate Cancer Clinical Trials
2026
·
Vitor Abreu de Góes
, Miguel Zugman
, et al.
·
JCO Global Oncology
·
1
Long-term clinical outcomes with Clostridium butyricum MIYAIRI 588 (CBM588) and TOPOSCORE assessment in patients receiving immune checkpoint inhibitor (ICI)-based combinations for metastatic renal cell carcinoma (mRCC).
2026
·
Ali Moradi
, Nazli Dizman
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Genomic Risk Classifiers in Localized Prostate Cancer: Precise but Not Standardized
2025
·
Vitor Góes
, Yu Jun Li
, et al.
·
JCO Precision Oncology
·
1
Vulnerability index impacts distribution of prostate cancer clinical trials in the United States
2026
·
Vitor Abreu de Goes
, Benjamin Mercier
, et al.
·
Frontiers in Oncology
PDF
18 Prediction of Immune-Related Adverse Events (irAEs) with Hematologic Markers in Patients Receiving First-Line Immune Checkpoint Inhibitor (ICI)-Based Therapy in Metastatic Renal Cell Carcinoma (mRCC)
2026
·
Rahul Winayak
, Xiaochen Li
, et al.
·
The Oncologist
PDF
IUC26666-91 Prediction of immune-related adverse events (irAEs) with hematologic markers in patients receiving first-line immune checkpoint inhibitor (ICI)-based therapy in metastatic renal cell carcinoma (mRCC)
2026
·
R Winayak
, X Li
, et al.
·
The Oncologist
Genomic Characterization of Urothelial Carcinoma and Sarcomatoid Carcinoma of the Upper Urinary Tract
2026
·
Salvador Jaime-Casas
, Nicholas J. Salgia
, et al.
·
Cancers
PDF
PSA nadir–stratified outcomes of ARPI doublet and docetaxel triplet therapy in metastatic prostate cancer.
2026
·
Miguel Zugman
, Jennifer Rider
, et al.
·
Journal of Clinical Oncology
Treatment-free survival (TFS) in patients with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV)–based therapy.
2026
·
Salvador Jaime-Casas
, Koral U. Shah
, et al.
·
Journal of Clinical Oncology
Biomarker-defined outcomes in metastatic clear cell renal cell carcinoma (mccRCC) receiving first-line (1L) immune checkpoint inhibitor-based therapy.
2026
·
Koral U. Shah
, Jennifer Rider
, et al.
·
Journal of Clinical Oncology
PDF
Use of ALK Inhibitors in Patients With Nonlung Malignancies Bearing ALK Alteration Prolongs Treatment Duration
2026
·
Vitor Abreu de Góes
, Matthew Lee
, et al.
·
JCO Precision Oncology
Abstract 3911: Use of ALK inhibitors in patients with non-lung malignancies bearing ALK alteration prolongs treatment duration.
2026
·
Vitor Abreu de Goes
, Miguel Zugman
, et al.
·
Cancer Research
Severe bleeding diathesis after dental extractions: a complex case of coagulation disturbances in a patient with multiple myeloma
2026
·
Fernanda de Paula Eduardo
, Leticia Mello Bezinelli
, et al.
·
Einstein (São Paulo)
PDF
Genomic characterization of upper tract urothelial carcinoma (UTUC) with or without sarcomatoid differentiation.
2026
·
Salvador Jaime-Casas
, Nicholas Salgia
, et al.
·
Journal of Clinical Oncology
PDF
Geographic disparities in the availability of renal cell carcinoma (RCC) clinical trials in the United States (US).
2026
·
George Zhang
, Daniela V. Castro
, et al.
·
Journal of Clinical Oncology
PDF
Availability of clinical trials investigating prostate cancer (PC) in the United States (US).
2026
·
Benjamin Mercier
, Vitor Abreu de Goes
, et al.
·
Journal of Clinical Oncology
Regional variations in bladder cancer (BC) clinical trial availability within the United States (US).
2026
·
Koral U. Shah
, George Zhang
, et al.
·
Journal of Clinical Oncology
PDF
351P Association of G-coupled protein receptor 65 (GPR65), a novel therapeutic target, with immune cell subsets in metastatic renal cell carcinoma (mRCC)
2025
·
K. Shah
, N.J. Salgia
, et al.
·
Immuno-Oncology Technology
Show more works
View as search
Works count:
29
Citation count:
129
H-index:
3
I10-index:
1
Year
Topic
Type